Fintel reports that on September 25, 2026, Craig-Hallum initiated coverage of TELA Bio (NASDAQGM:TELA) with a Buy recommendation.
On the same day, September 25, 2026, the latest closing price for TELA Bio was $1.28, following a pre-action close of $1.27 on September 24, 2026. Over a one-week period, the stock experienced a price change of +2.40% from a baseline close of $1.25 on September 18, 2026. Looking back further, the one-month price change was +82.86% from a baseline close of $0.70 on August 25, 2026.
Prior to this rating action, consensus target price data from September 15, 2026, showed a current consensus target mean of $2.14 and a median of $2.04. This mean target represents an implied change of +67.34% from the stock's valuation. The prior consensus target mean was also $2.14 as of August 28, 2026, representing a consensus target revision of 0.00%.
In its latest quarterly financial results reported on August 10, 2026, TELA Bio posted an actual EPS of -0.2, compared to an estimated EPS of -0.1818. The company's actual revenue for the quarter was $19,291,000.00, which fell short of the estimated revenue of $20,408,568.00.
The broader analyst sentiment for the company has remained steady. As of the current recommendation period starting September 1, 2026, the total number of recommendations is 11, with 81.8% positive, 18.2% hold, and 0.0% negative. Specifically, there are 3 strong buy, 6 buy, 2 hold, 0 sell, and 0 strong sell recommendations. This is identical to the prior recommendation period of August 1, 2026, which also recorded 11 total recommendations, consisting of 3 strong buy, 6 buy, 2 hold, 0 sell, and 0 strong sell recommendations, representing 81.8% positive, 18.2% hold, and 0.0% negative ratings.
Recent analyst actions
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.